Genezen at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Genezen brings 6 presentations to ESGCT 2026 in Hamburg. Its contributions centre on producing lentiviral and retroviral vectors to clinical standards, including formulation changes that improve recovery after filling. Other strands cover analytical methods for residual host cell DNA, process validation monitoring and AAV purification.
| Organization | ESGCT 2026 Attendance |
|---|---|
Genezen Indianapolis, Indiana | |
Contract development and manufacturing organisation for cell and gene therapies, producing lentiviral and retroviral vectors from plasmid design and cell line development to GMP manufacturing. | Poster Wed Oct 28 1:30pm–3:30pm Addition of sugar to final formulation buffer improves lentiviral and γ-retroviral vector recovery in sterile filtration by potentially stabilizing the viral vector Poster Wed Oct 28 1:30pm–3:30pm One and done: agile Cmc strategies for N-of-1 gene therapies Poster Thu Oct 29 2:00pm–4:00pm A dual optimization strategy: refining IEX elution and eliminating citric acid to improve AAV empty and full capsid separation Poster Thu Oct 29 2:00pm–4:00pm Continuous monitoring of cell and gene therapy processes in stage 3 of Process validation lifecycle Poster Thu Oct 29 2:00pm–4:00pm Development of a no-extraction ddPCR-based method for residual host cell DNA quantitation and sizing in therapeutic viral vectors Poster Thu Oct 29 2:00pm–4:00pm Screening of transfection process parameters related to the complexation reaction between the transfection reagent and plasmid DNS for the impact on rAAV titer in HEK cell host |
Instantly find 20 buyers from Genezen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction